ArticleOncogenesis2019

Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI.

Kimio Yonesaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.